Dermatitis News and Research

Latest Dermatitis News and Research

Two antioxidant supplements effective in treating mice with skin-picking disorder

Two antioxidant supplements are effective in treating skin-picking disorder in mice, according to a study led by a Stanford University School of Medicine researcher.

14 Jul 2015

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent® (alirocumab) Injection met its primary endpoint.

9 Jul 2015

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Cosmederm Bioscience, Inc. today announced the expansion of its itch-relief product line, TriCalm, with the new TriCalm Clinical Repair Cream and TriCalm Extra Strength Spray. Following the success of the company's initial product, TriCalm Hydrogel, these two new offerings strategically expand the brand's line of steroid-free, anti-itch products to further benefit sufferers of itch.

29 Jun 2015

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO).

26 Jun 2015

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon selection.

25 Jun 2015

$Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC$

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.

19 Jun 2015

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Atopix Therapeutics Limited, a UK biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announced that it has raised additional development capital to advance its lead product OC459 for the treatment of asthma.

17 Jun 2015

A third of people avoid social situations due to uncontrolled dandruff, reveals anonymous survey

A third of people admitted to avoiding social situations as a result of emotional distress caused by their dandruff, according to new survey results released today by the British Skin Foundation(BSF) in conjunction with the world’s no. 1 anti-dandruff shampoo, Head & Shoulders (H&S).

12 Jun 2015

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.

11 Jun 2015

New PlasmaDerm solution facilitates faster healing of wounds

Many people suffer from skin disorders. Open wounds are a particularly acute problem, especially among the elderly. PlasmaDerm, a new medical technology solution, uses plasma to facilitate faster healing of wounds.

10 Jun 2015

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of the investigational therapy Praluent (alirocumab) Injection.

9 Jun 2015

Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Helsinn, the Swiss Group focused on building quality cancer care, announces today that its recently launched Helsinn Integrative Care division is meeting the cancer community at booth 6033 at the American Society of Clinical Oncology Annual Meeting, May 29-June 2, Chicago, Illinois.

2 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

1 Jun 2015

Fragrance chemical linalyl acetate could cause allergic eczema

Linalyl acetate, a fragrance chemical that is one of the main constituents of the essential oil of lavender, is not on the list of allergenic compounds pursuant to the EU Cosmetics Directive. Thus, it does not need to be declared on cosmetic products sold within the EU. Recent studies at the University of Gothenburg have shown that linalyl acetate can cause allergic eczema.

30 May 2015

Novel survey shows high rates of tattoo-related infection, itching and swelling in New Yorkers

In what they believe to be the first survey of its kind in the United States, researchers at NYU Langone Medical Center have found that as many as 6 percent of adult New Yorkers who get "inked" — in other words, those who get a tattoo — have experienced some form of tattoo-related rash, severe itching or swelling that lasted longer than four months and, in some cases, for many years.

28 May 2015

University of Gothenburg studies reveal that linalyl acetate can trigger allergic eczema

28 May 2015

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults.

28 May 2015

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.

21 May 2015

New research points to potential therapeutic target for treating multiple sclerosis

New research into the causes of the excessive inflammation that drives multiple sclerosis has identified a faulty "brake" within immune cells, a brake that should be controlling the inflammation. This points to a potential target for developing new therapies to treat multiple sclerosis and could have important implications for other autoimmune diseases, such as the colon disease colitis and the chronic skin condition atopic dermatitis.

20 May 2015

Dermatitis News and Research

Latest Dermatitis News and Research

Two antioxidant supplements effective in treating mice with skin-picking disorder

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Atopix raises additional development capital to investigate OC459 for treatment of asthma

A third of people avoid social situations due to uncontrolled dandruff, reveals anonymous survey

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

New PlasmaDerm solution facilitates faster healing of wounds

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Fragrance chemical linalyl acetate could cause allergic eczema

Novel survey shows high rates of tattoo-related infection, itching and swelling in New Yorkers

University of Gothenburg studies reveal that linalyl acetate can trigger allergic eczema

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

New research points to potential therapeutic target for treating multiple sclerosis

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Dermatitis News and Research

Latest Dermatitis News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in